All of the shares of common stock to be sold in the proposed offering will be sold by Kyverna. J.P. Morgan, Leerink Partners, Morgan Stanley and Wells Fargo Securities are acting as joint book-running managers for the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics’ Promising KYSA-8 Study and Strategic Plans Bolster Buy Rating
- Leerink raises Kyverna price target, says KYSA-8 study results transformative
- Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley
- Kyverna Therapeutics: Promising Outlook with Breakthrough CAR-T Therapy in Autoimmune Diseases
- Midday Fly By: Intel eyes SambaNova, Cencora to acquire OneOncology